Abstract
Therapy-induced senescence (TIS), a lasting chemotherapy-evoked proliferative arrest of tumor cells, has gained increasing attention by cancer researchers because of its’ profound biological implications, and by clinical oncologists due to its potential contribution to the long-term outcome of cancer patients post-treatment. Although both apoptosis and senescence represent therapy-inducible, ultimate cell-cycle exit programs, mediated via DNA damage response signaling, apoptotic cell death as the faster and often quantitatively more prominent tumor response has been in the scientific focus for decades. The more recently recognized TIS as another “safeguard” response of cancer cells that were never primed for or failed to execute apoptosis, not only reflects a more complex “arrest-plus-other features” cell-autonomous condition but produces non-cell-autonomous phenotypes at the tumor site, collectively impinging on tumor control and clinical outcome. Hence, TIS research is gaining pivotal interest from both a tumor biological and a therapeutic perspective, and the development of non-DNA damaging, senescence-evoking therapeutics is about to become a major research objective. In this chapter, we describe a well-characterized, genetically controlled TIS model system based on primary BCL2-expressing Eμ-myc transgenic lymphoma cells harboring defined genetic lesions and provide protocols for co-staining of either senescence-associated β-galactosidase (SA-β-gal) activity or trimethylated lysine 9 of histone H3 (H3K9me3) together with Ki67 to detect the senescent status of therapy-exposed cancer cells.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Collado M, Blasco MA, Serrano M (2007) Cellular senescence in cancer and aging. Cell 130:223–233
Kuilman T, Michaloglou C, Mooi WJ et al (2010) The essence of senescence. Genes Dev 24:2463–2479
Salama R, Sadaie M, Hoare M et al (2014) Cellular senescence and its effector programs. Genes Dev 28:99–114
van Deursen JM (2014) The role of senescent cells in ageing. Nature 509:439–446
Bartkova J, Rezaei N, Liontos M et al (2006) Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444:633–637
Di Micco R, Fumagalli M, Cicalese A et al (2006) Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444:638–642
Braig M, Lee S, Loddenkemper C et al (2005) Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436:660–665
Narita M, Nunez S, Heard E et al (2003) Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113:703–716
Baker DJ, Wijshake T, Tchkonia T et al (2011) Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 479:232–236
Collado M, Serrano M (2006) The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer 6:472–476
Dimri GP, Lee X, Basile G et al (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 92:9363–9367
Sharpless NE, Sherr CJ (2015) Forging a signature of in vivo senescence. Nat Rev Cancer 15:397–408
Chang BD, Broude EV, Dokmanovic M et al (1999) A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 59:3761–3767
Chang BD, Xuan Y, Broude EV et al (1999) Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 18:4808–4818
Dorr JR, Yu Y, Milanovic M et al (2013) Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature 501:421–425
Jing H, Kase J, Dorr JR et al (2011) Opposing roles of NF-kappaB in anti-cancer treatment outcome unveiled by cross-species investigations. Genes Dev 25:2137–2146
Schmitt CA, Fridman JS, Yang M et al (2002) Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 1:289–298
Schmitt CA, Fridman JS, Yang M et al (2002) A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109:335–346
Schmitt CA, Lowe SW (2002) Apoptosis and chemoresistance in transgenic cancer models. J Mol Med 80:137–146
Schmitt CA, Rosenthal CT, Lowe SW (2000) Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med 6:1029–1035
te Poele RH, Okorokov AL, Jardine L et al (2002) DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 62:1876–1883
Acosta JC, Ferrandiz N, Bretones G et al (2008) Myc inhibits p27-induced erythroid differentiation of leukemia cells by repressing erythroid master genes without reversing p27-mediated cell cycle arrest. Mol Cell Biol 28:7286–7295
Acosta JC, O’Loghlen A, Banito A et al (2008) Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133:1006–1018
Acosta JC, O’Loghlen A, Banito A et al (2008) Control of senescence by CXCR2 and its ligands. Cell Cycle 7:2956–2959
Acosta JC, Snijders AP, Gil J (2013) Unbiased characterization of the senescence-associated secretome using SILAC-based quantitative proteomics. Methods Mol Biol 965:175–184
Coppe JP, Patil CK, Rodier F et al (2008) Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6:2853–2868
Krtolica A, Parrinello S, Lockett S et al (2001) Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci U S A 98:12072–12077
Kuilman T, Michaloglou C, Vredeveld LC et al (2008) Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133:1019–1031
Kuilman T, Peeper DS (2009) Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer 9:81–94
Kang TW, Yevsa T, Woller N et al (2011) Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 479:547–551
Xue W, Zender L, Miething C et al (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445:656–660
Kaplon J, Zheng L, Meissl K et al (2013) A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature 498:109–112
Shah PP, Donahue G, Otte GL et al (2013) Lamin B1 depletion in senescent cells triggers large-scale changes in gene expression and the chromatin landscape. Genes Dev 27:1787–1799
Young AR, Narita M (2009) SASP reflects senescence. EMBO Rep 10:228–230
Zhang R, Poustovoitov MV, Ye X et al (2005) Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA. Dev Cell 8:19–30
Reimann M, Lee S, Loddenkemper C et al (2010) Tumor stroma-derived TGF-beta limits Myc-driven lymphomagenesis via Suv39h1-dependent senescence. Cancer Cell 17:262–272
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media New York
About this protocol
Cite this protocol
Fan, D.N.Y., Schmitt, C.A. (2017). Detecting Markers of Therapy-Induced Senescence in Cancer Cells. In: Nikiforov, M. (eds) Oncogene-Induced Senescence. Methods in Molecular Biology, vol 1534. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6670-7_4
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6670-7_4
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6668-4
Online ISBN: 978-1-4939-6670-7
eBook Packages: Springer Protocols